We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

PTHrP and Osteoporosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00021827
Recruitment Status : Completed
First Posted : August 6, 2001
Last Update Posted : March 2, 2010
Information provided by:

August 4, 2001
August 6, 2001
March 2, 2010
June 1999
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00021827 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
PTHrP and Osteoporosis
Pathophysiology of PTH-related Protein in Humans.
PTH-related protein, or ''PTHrP'', is a hormone which was discovered in 1987. As its name implies, it is closely related to another hormone discovered in the 1920's named parathyroid hormone or ''PTH''. PTH has been shown to be effective in treating osteoporosis in both animals and humans. PTHrP has been shown to be effective in treating osteoporosis in laboratory animals, and there are strong scientific reasons to think that it may be effective in humans as well. However, no human trials with PTHrP in the treatment of osteoporosis have been performed. The studies in this trial are focussed on determining whether PTHrP can indeed increase bone mass in postmenopausal women with osteoporosis, when administered daily by subcutaneous injection for three months.
Not Provided
Phase 2
Allocation: Randomized
Masking: Double
Primary Purpose: Treatment
Drug: Parathyroid hormone-related protein or ''PTHrP''
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Not Provided
December 2001
Not Provided

Inclusion Criteria:

  • Healthy caucasian postmenopausal females between 50-75 years of age with low bone mineral density at the lumbar spine or hip as measured using dual energy x-ray absorptiometry or DXA.
  • ON estrogen replacement treatment for at least three years.

Exclusion Criteria:

  • Heart, vascular, kidney, liver, lung, hormonal, musculo-skeletal disease (other than osteoporosis), rheumatic, blood diseases are exclusion criteria.
  • High blood pressure
  • Pregnancy
  • Cancer
  • Alcohol or drug dependence
  • Prior use of a drug treatment for osteoporosis such as PTH, bisphosphonates, raloxifene, or calcitonin within the preceding five years
Sexes Eligible for Study: Female
50 Years to 75 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
PTHrP and Osteo (completed)
RO-1 DK 51081
Not Provided
Not Provided
Not Provided
Not Provided
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Not Provided
Principal Investigator: Andrew F. Stewart University of Pittsburgh
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
March 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP